Johnson & Johnson: JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
Read full article »
Johnson & Johnson is a New Jersey-based firm that engages in research, manufacturing and sale of healthcare products including consumer, pharmaceutical and medical devices.
Read more